{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:21:44Z","timestamp":1781796104922,"version":"3.54.5"},"reference-count":18,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"Bristol-Myers Squibb"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2018,2,1]]},"DOI":"10.1080\/03007995.2017.1399870","type":"journal-article","created":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T23:38:08Z","timestamp":1509665888000},"page":"353-360","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":28,"title":["Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US"],"prefix":"10.1080","volume":"34","author":[{"given":"Meg","family":"Franklin","sequence":"first","affiliation":[{"name":"Franklin Pharmaceutical Consulting LLC, Rock Hill, SC, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Burns","sequence":"additional","affiliation":[{"name":"Center for Observational Research and Data Sciences, Princeton, NJ, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Perez","sequence":"additional","affiliation":[{"name":"Mu Sigma, Northbrook, IL, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Yerragolam","sequence":"additional","affiliation":[{"name":"Mu Sigma Business Solutions, Karnataka, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinara","family":"Makenbaeva","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb Company, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,11,30]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.04.002"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"CIT0006","volume-title":"Sprycel (dasatinib) [prescribing information]","year":"2011"},{"key":"CIT0007","volume-title":"Tasigna (nilotinib) [prescribing information]","year":"2011"},{"key":"CIT0008","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia v.1.2017. Available at: NCCN.org. [Last accessed: January 17, 2017]"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.09.016"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210378913"},{"key":"CIT0011","unstructured":"Hughes T, le Coutre PD, Jootar S, et\u00a0al. ENESTnd 5-year follow-up: continued benefit of frontline nilotinib vs imatinib in patients with CML in chronic phase. 19th Congress of the European Hematology Association. Milan, Italy, 12\u201315 June 2014"},{"key":"CIT0012","unstructured":"Truven Health Analytics: Marketscan Research Databases. Available at: http:\/\/truvenhealth.com\/your-healthcare-focus\/analytic-research\/marketscan-research-databases [Last accessed 30 May 2017]"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5580"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.01.024"},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1182\/blood.V110.11.4588.4588","volume":"110","author":"Le Coutre T","year":"2007","journal-title":"Blood"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26249"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.12.011"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.104075"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2017.1399870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T08:28:33Z","timestamp":1599294513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2017.1399870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,30]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2,1]]}},"alternative-id":["10.1080\/03007995.2017.1399870"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2017.1399870","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}